{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:32:25Z","timestamp":1789561945960,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20ck0106508h0002"],"award-info":[{"award-number":["20ck0106508h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19ck0106508h0001"],"award-info":[{"award-number":["JP19ck0106508h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007207","name":"Toray Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007207","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009337","name":"Saitama Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.annonc.2020.05.031","type":"journal-article","created":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T18:24:56Z","timestamp":1591467896000},"page":"1198-1206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":140,"title":["Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients"],"prefix":"10.1016","volume":"31","author":[{"given":"Y.","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Namikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Uchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kiniwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Takenouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Uhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Funakoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Teramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Isei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Shibayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2020.05.031_bib1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cll.2011.03.005","article-title":"Acral lentiginous melanoma","volume":"31","author":"Piliang","year":"2011","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.annonc.2020.05.031_bib2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archdermatol.2008.609","article-title":"Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005","volume":"145","author":"Bradford","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annonc.2020.05.031_bib3","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/archderm.1987.01660340093027","article-title":"Melanoma within a southwestern Hispanic population","volume":"123","author":"Black","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annonc.2020.05.031_bib4","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/cncr.25355","article-title":"The expanding melanoma burden in California hispanics: Importance of socioeconomic distribution, histologic subtype, and anatomic location","volume":"117","author":"Pollitt","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2020.05.031_bib5","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1245\/s10434-016-5394-x","article-title":"Melanoma in Mexico: clinicopathologic features in a population with predominance of acral lentiginous subtype","volume":"23","author":"Lino-Silva","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.annonc.2020.05.031_bib6","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/cam4.2110","article-title":"Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma","volume":"8","author":"Fujisawa","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.annonc.2020.05.031_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2407-11-85","article-title":"Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases","volume":"11","author":"Chi","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.annonc.2020.05.031_bib8","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3349\/ymj.2010.51.4.562","article-title":"Treatment and outcomes of melanoma in acral location in Korean patients","volume":"51","author":"Roh","year":"2010","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.annonc.2020.05.031_bib9","first-page":"65","article-title":"Melanoma in black South Africans","volume":"180","author":"Hudson","year":"1995","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.annonc.2020.05.031_bib10","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.05.031_bib11","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.05.031_bib12","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1056\/NEJMc1512354","article-title":"Melanomas and mechanical stress points on the plantar surface of the foot","volume":"374","author":"Minagawa","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.05.031_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2020.05.031_bib14","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1634\/theoncologist.2015-0522","article-title":"Prognosis of mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma from the time of first metastasis","volume":"21","author":"Kuk","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2020.05.031_bib15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","article-title":"Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial","volume":"5","author":"Ascierto","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2020.05.031_bib16","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.05.031_bib17","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.05.031_bib18","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.05.031_bib19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.annonc.2020.05.031_bib20","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.30259","article-title":"The efficacy of anti-PD-1 agents in acral and mucosal melanoma","volume":"122","author":"Shoushtari","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2020.05.031_bib21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2019.07.010","article-title":"Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)","volume":"119","author":"Nathan","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2020.05.031_bib22","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.tranon.2019.02.007","article-title":"A\u00a0phase Ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE-151)","volume":"12","author":"Si","year":"2019","journal-title":"Transl Oncol"},{"key":"10.1016\/j.annonc.2020.05.031_bib23","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.annonc.2020.05.031_bib24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/labinvest.2016.143","article-title":"Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas","volume":"97","author":"Rawson","year":"2017","journal-title":"Lab Invest"},{"key":"10.1016\/j.annonc.2020.05.031_bib25","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2020.05.031_bib26","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.05.031_bib27","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.05.031_bib28","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2020.05.031_bib29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jdermsci.2015.07.012","article-title":"Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients","volume":"80","author":"Sakaizawa","year":"2015","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.annonc.2020.05.031_bib30","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/bjd.17434","article-title":"Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients","volume":"180","author":"Maeda","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annonc.2020.05.031_bib31","doi-asserted-by":"crossref","first-page":"ix105","DOI":"10.1093\/annonc\/mdy439.003","article-title":"Interim analysis of prospective observational study on the efficacy of nivolumab for Japanese advanced melanoma patients (CREATIVE study)","volume":"29","author":"Nakamura","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.05.031_bib32","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma","volume":"305","author":"Carvajal","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.annonc.2020.05.031_bib33","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin","volume":"31","author":"Hodi","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.05.031_bib34","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.05.031_bib35","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/1078-0432.CCR-11-1987","article-title":"Sunitinib therapy for melanoma patients with KIT mutations","volume":"18","author":"Minor","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2020.05.031_bib36","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/cncr.30663","article-title":"A\u00a0phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: a trial of the ECOG-ACRIN Cancer Research Group (E2607)","volume":"123","author":"Kalinsky","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2020.05.031_bib37","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1158\/1078-0432.CCR-14-1630","article-title":"Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition","volume":"21","author":"Carvajal","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2020.05.031_bib38","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2018.09.025","article-title":"Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: an open-label, single-arm, multicentre phase II study","volume":"105","author":"Namikawa","year":"2018","journal-title":"Eur J Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420398732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420398732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:26:20Z","timestamp":1778765180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420398732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0923753420398732"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2020.05.031","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2020.05.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}